Logo del repository
  1. Home
 
Opzioni

Real-world experience on off-label use of imiquimod 5% as an adjuvant therapy after surgery or as a monotherapy for lentigo maligna

Lallas, A
•
Moscarella, E
•
Kittler, H
altro
Argenziano, G
2021
  • journal article

Periodico
BRITISH JOURNAL OF DERMATOLOGY
Abstract
Because of the tendency of lentigo maligna (LM) for subclinical extension, staged excisions with margin control achieve lower recurrence rates than conventional wide local excision (0-9.5% vs 8-20%). However, these surgical techniques are limited by their requirement in time, costs and training.
DOI
10.1111/bjd.20407
WOS
WOS:000669608900001
Archivio
http://hdl.handle.net/11368/2991665
info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85109065781
https://onlinelibrary.wiley.com/doi/10.1111/bjd.20407
Diritti
open access
license:digital rights management non definito
license:creative commons
license uri:http://creativecommons.org/licenses/by-nc-nd/4.0/
FVG url
https://arts.units.it/request-item?handle=11368/2991665
Soggetti
  • melanoma

  • lentigo maligna

  • imiquimod

  • treatment

  • mohs' surgery

  • recurrence

Scopus© citazioni
3
Data di acquisizione
Jun 7, 2022
Vedi dettagli
Web of Science© citazioni
15
Data di acquisizione
Feb 29, 2024
google-scholar
Get Involved!
  • Source Code
  • Documentation
  • Slack Channel
Make it your own

DSpace-CRIS can be extensively configured to meet your needs. Decide which information need to be collected and available with fine-grained security. Start updating the theme to match your nstitution's web identity.

Need professional help?

The original creators of DSpace-CRIS at 4Science can take your project to the next level, get in touch!

Realizzato con Software DSpace-CRIS - Estensione mantenuta e ottimizzata da 4Science

  • Impostazioni dei cookie
  • Informativa sulla privacy
  • Accordo con l'utente finale
  • Invia il tuo Feedback